Physician profile
Marcel Simo
NPI 1972734002
$5,517.00
in general payments reported to CMS, 2019-2025
23 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $538 · 2023: $705 · 2024: $1,774 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,486.54 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,325.65 | 2021-2025 | Caplyta |
| Abbvie INC. | $938.38 | 2021-2025 | |
| Axsome Therapeutics, INC. | $506.61 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $417.89 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $374.22 | 2022-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $318.38 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $318.00 | 2024-2025 | Uzedy |
| Corium, LLC | $298.01 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $260.13 | 2022-2025 | Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $183.43 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $158.99 | 2024 | Ozempic, Rybelsus |
| Alkermes, INC. | $96.22 | 2025 | Lybalvi, Aristada |
| Lundbeck LLC | $55.67 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $52.51 | 2025 | Spravato |
| Indivior INC. | $49.34 | 2025 | Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $30.47 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $28.33 | 2021-2022 | |
| Cipher Pharmaceuticals US LLC | $22.52 | 2025 | Spinosad, Natroba |
| Ironshore Pharmaceuticals INC. | $19.26 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.52 | 2021 | |
| Pfizer INC. | $14.29 | 2023 | |
| Glaxosmithkline, LLC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Simo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.